Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on Carbonyl Reductase Mutants. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel carbonyl reductase mutants enable high-yield rosuvastatin intermediate production with reduced costs and enhanced supply chain reliability for global pharmaceutical manufacturers.
Patent CN104099305A reveals stable CgKR1 mutants for Clopidogrel intermediates. Enhances purity and supply chain reliability for global pharmaceutical manufacturing.